Alternative Data for Grail
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 64 | Sign up | Sign up | Sign up |
| Sentiment | 88 | Sign up | Sign up | Sign up |
| Webpage traffic | 85,000 | Sign up | Sign up | Sign up |
| Employee Rating | 58 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 20 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,794 | Sign up | Sign up | Sign up |
| Instagram Followers | 938 | Sign up | Sign up | Sign up |
| Reddit Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,580 | Sign up | Sign up | Sign up |
| Threads Followers | N/A | Sign up | Sign up | Sign up |
| X Followers | 16,991 | Sign up | Sign up | Sign up |
| X Mentions | 43 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,670 | Sign up | Sign up | Sign up |
| News Mentions | 15 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 31 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,082 | Sign up | Sign up | Sign up |
About Grail
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection.
| Price | $48.67 |
| Target Price | Sign up |
| Volume | 1,588,581 |
| Market Cap | $2.03B |
| Year Range | $31.42 - $116.06 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Wind farm discovers 1877 ‘ghost ship’ but the $500 million ‘Holy Grail’ wreck is still missingMarch 6 - The Times of India |
 |
The Holy Grail of Eris ‒ Episode 9March 5 - Anime News Network |
 |
History You Can’t Manufacture: Inside the Auction for Baseball’s New ‘Holy Grail’March 3 - Onmantel.com |
 |
Why did the Grail cancer test trial fail? #healthFebruary 26 - Alltoc.com |
 |
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED)February 19 - Benzinga |
 |
Why Grail Stock Is Sinking FridayFebruary 19 - Benzinga |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 36M | 50M | -14M | -89M | -80M | -2.460 |
| Q2 '25 | 36M | 53M | -18M | -114M | -92M | -3.180 |
| Q1 '25 | 32M | 52M | -20M | -106M | -114M | -3.100 |
| Q4 '24 | 38M | 54M | -16M | -97M | -97M | -2.890 |
| Q3 '24 | 29M | 51M | -22M | -126M | -144M | -3.500 |
Insider Transactions View All
| Freidin Aaron filed to sell 306,475 shares at $46.7. March 9 '26 |
| RAGUSA ROBERT P filed to sell 642,084 shares at $46.7. March 9 '26 |
| Ofman Joshua J. filed to sell 432,881 shares at $46.7. March 9 '26 |
| RAGUSA ROBERT P filed to sell 642,342 shares at $47.9. March 9 '26 |
| Ofman Joshua J. filed to sell 432,982 shares at $47.9. March 9 '26 |
Similar companies
Read more about Grail (GRAL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, threads followers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Grail
The Market Cap of Grail is $2.03B.
Currently, the price of one share of Grail stock is $48.67.
The GRAL stock price chart above provides a comprehensive visual representation of Grail's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Grail shares. Our platform offers an up-to-date GRAL stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Grail (GRAL) does not offer dividends to its shareholders. Investors interested in Grail should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Grail are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
